Prelude Therapeutics prices $90M public offering of common stock and pre-funded warrants

Prelude Therapeutics Inc

Offering of 18,018,014 common shares at $4.44/share and pre-funded warrants for 2,252,252 shares at $4.4399.
Gross proceeds ~$90M; net proceeds ~$85.5M after expenses.
Led by RA Capital Management and Soleus Capital; closes April 21, 2026.
Proceeds to fund R&D, working capital; extends cash runway into Q2 2028.
Underwriters: Goldman Sachs, Evercore ISI, Citizens Capital Markets.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Prelude Therapeutics Inc entered into Underwriting Agreement with Goldman Sachs & Co. LLC and Evercore Group L.L.C. (effective 2026-04-20).

Action: entry
Agreement: underwriting
Counterparty: Goldman Sachs & Co. LLC and Evercore Group L.L.C.
Effective: 2026-04-20

Exact text from the filing

On April 20, 2026, Prelude Therapeutics Incorporated (“Prelude”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC and Evercore Group L.L.C. as representatives (the “Representatives”) of the underwriters named therein

View on SEC.gov

Browse all material agreements →

Prelude Therapeutics Inc filing history →

Source: SEC EDGAR

accession 0001193125-26-164510

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.